OCARINA II, Phase III Study: Results of Subcutaneous Ocrelizumab Administration in Patients with Multiple Sclerosis

Authors
Category Primary study
JournalNeurology
Year 2024
This article has no abstract
Epistemonikos ID: 64294fea2f56cf059b32e989003167cc43669a34
First added on: Feb 19, 2025